Status:
COMPLETED
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Conjunctivitis, Seasonal Allergic
Conjunctivitis, Giant Papillary
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
Detailed Description
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice after marketing authorization of Lotemax oph...
Eligibility Criteria
Inclusion
- Subjects who have been treated with the study drug at least once and completed safety follow-up.
- Subjects who have been treated with the study drug at least once and completed the clinical efficacy assessment.
Exclusion
- Subjects not treated with study drug at least once.
Key Trial Info
Start Date :
August 5 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 19 2015
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT01437982
Start Date
August 5 2010
End Date
October 19 2015
Last Update
November 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch & Lomb Korea Ltd
Seoul, South Korea, 135-280